Actions
Milan
,
Italy
28 September - 2 October 2026
62nd Annual Meeting of the European Association for the Study of Diabetes (EASD 2026)
Interview with Professor Tina Vilsbøll, Senior Medical Officer, Novo Nordisk A/S
Medical Commentary: Draft ADA/EASD Consensus Report 2026
In this interview, Professor Tina Vilsbøll shares her clinical perspective on the draft ADA/EASD Consensus Report 2026, following its release for public comment at ADA 2026 and ahead of the final report at EASD 2026. She reflects on the growing role of GLP-1–based therapy, the shift from glucose-focused care to a broader view of the whole patient, and the increasing focus on comorbidities including cardiovascular, kidney and liver disease.
Presentation schedule and materials
Monday, 28 September 2026
09:00
- 16:30
CEST
Symposium
Advancing person-centred care across the cardiometabolic spectrum through scientific innovation
Anna Secher
;
Carel le Roux
;
Chantal Mathieu
;
Erin Bohula
;
Harpreet Bajaj
;
John Buse
;
Kirsi Pietiläinen
;
Philip Newsome
MATERIALS AVAILABLE
Coming soon
Tuesday, 29 September 2026
16:15
- 16:45
CEST
Symposium
Essence of MASH management: practical strategies to improve patient outcomes in diabetes clinics
Alice Cheng
;
Philip Newsome
MATERIALS AVAILABLE
Coming soon
Thursday, 01 October 2026
18:45
- 20:15
CEST
Symposium
Changing the trajectory of chronic metabolic disease: The evolving role of GLP-1-based care
Alice Cheng
;
Kirsi Pietiläinen
;
Eric Lawitz
MATERIALS AVAILABLE
Coming soon
Actions
Keywords